Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.45
USD
|
+10.58%
|
|
+8.15%
|
-21.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
128.2
|
196.9
|
105.6
|
71.34
|
112.4
|
88.62
|
Enterprise Value (EV)
1 |
128.2
|
196.9
|
105.6
|
71.34
|
112.4
|
88.62
|
P/E ratio
|
-6.99
x
|
-6.11
x
|
-53.6
x
|
-7.83
x
|
-110
x
|
49.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
134
x
|
5,048
x
|
4.84
x
|
3.36
x
|
3.55
x
|
2.14
x
|
EV / Revenue
|
134
x
|
5,048
x
|
4.84
x
|
3.36
x
|
3.55
x
|
2.14
x
|
EV / EBITDA
|
-7,062,444
x
|
-7,439,759
x
|
-102,188,277
x
|
-
|
-
|
-
|
EV / FCF
|
-6,704,926
x
|
-8,789,785
x
|
-22,317,228
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,807
|
24,214
|
24,606
|
25,297
|
25,658
|
25,688
|
Reference price
2 |
7.200
|
8.130
|
4.290
|
2.820
|
4.380
|
3.450
|
Announcement Date
|
3/5/20
|
3/16/21
|
3/16/22
|
3/16/23
|
3/14/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
0.959
|
0.039
|
21.83
|
21.25
|
31.64
|
41.43
|
EBITDA
|
-18.15
|
-26.46
|
-1.033
|
-
|
-
|
-
|
EBIT
1 |
-18.6
|
-27.11
|
-1.495
|
-8.26
|
-1.192
|
2.812
|
Operating Margin
|
-1,939.62%
|
-69,515.38%
|
-6.85%
|
-38.87%
|
-3.77%
|
6.79%
|
Earnings before Tax (EBT)
1 |
-18.32
|
-27.97
|
-1.955
|
-9.021
|
-0.689
|
1.972
|
Net income
1 |
-18.32
|
-27.97
|
-1.955
|
-9.021
|
-0.936
|
1.972
|
Net margin
|
-1,910.32%
|
-71,717.95%
|
-8.95%
|
-42.45%
|
-2.96%
|
4.76%
|
EPS
2 |
-1.030
|
-1.330
|
-0.0800
|
-0.3600
|
-0.0400
|
0.0700
|
Free Cash Flow
|
-19.12
|
-22.4
|
-4.73
|
-
|
-
|
-
|
FCF margin
|
-1,993.95%
|
-57,425.64%
|
-21.67%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/16/21
|
3/16/22
|
3/16/23
|
3/14/24
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.775
|
6.093
|
2.176
|
7.358
|
3.219
|
8.498
|
5.304
|
12
|
7.028
|
7.313
|
8.3
|
10
|
10.8
|
12.3
|
EBITDA
|
-5.762
|
1.451
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-5.847
|
1.314
|
-5.087
|
-1.34
|
-2.895
|
1.062
|
-2.534
|
3.883
|
-0.548
|
-1.993
|
-
|
-
|
-
|
-
|
Operating Margin
|
-754.45%
|
21.57%
|
-233.78%
|
-18.21%
|
-89.93%
|
12.5%
|
-47.78%
|
32.37%
|
-7.8%
|
-27.25%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-6.094
|
1.039
|
-5.33
|
-1.558
|
-3.045
|
0.912
|
-2.66
|
4.559
|
-0.579
|
-2.009
|
-
|
-
|
-
|
-
|
Net income
|
-6.094
|
1.039
|
-5.33
|
-1.558
|
-3.045
|
0.912
|
-2.66
|
4.559
|
-0.579
|
-2.256
|
-
|
-
|
-
|
-
|
Net margin
|
-786.32%
|
17.05%
|
-244.94%
|
-21.17%
|
-94.59%
|
10.73%
|
-50.15%
|
38%
|
-8.24%
|
-30.85%
|
-
|
-
|
-
|
-
|
EPS
|
-0.2400
|
0.0400
|
-0.2100
|
-0.0600
|
-0.1200
|
0.0400
|
-0.1000
|
0.1800
|
-0.0200
|
-0.0900
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/16/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-19.1
|
-22.4
|
-4.73
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/16/21
|
3/16/22
|
3/16/23
|
3/14/24
|
-
|
Last Close Price
3.45
USD Average target price
10
USD Spread / Average Target +189.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.23% | 88.62M | | +5.31% | 70.44B | | +10.97% | 8.94B | | -16.83% | 4.75B | | +43.48% | 4.5B | | +3.20% | 3.85B | | +18.82% | 2.38B | | -21.36% | 2.34B | | -29.67% | 2.2B | | +8.38% | 1.96B |
Specialty & Advanced Pharmaceuticals
|